文献速递白血病造血干细胞移植与细胞治疗

基于移植前可测量残留病的预防性酪氨酸激酶抑制剂策略用于接受异基因造血干细胞移植的费城染色体阳性急性淋巴细胞白血病:一项前瞻性多中心队列研究

A prophylactic tyrosine kinase inhibitor strategy based on measurable residual disease pre-transplantation for Ph+ acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: A prospective multicenter cohort study.
PubMed 文献 · Am J Hematol · 2024-11-16

该前瞻性多中心队列研究纳入110例接受异基因造血干细胞移植的费城染色体阳性急性淋巴细胞白血病患者,按移植前可测量残留病状态分为预防性TKI组(38例,MRD阳性)和对照组(72例,MRD阴性)。预防性TKI组与对照组的4年累积复发率分别为25.3%和20.3%(HR=1.272,p=.549),无复发生存率、总生存率及白血病无病生存率均无显著差异。作者认为移植前MRD阳性患者移植后预防性使用TKI可获得与移植前MRD阴性且移植后未用TKI者相当的结局。

要点

  • 移植前MRD阳性者接受预防性TKI,4年累积复发率25.3%,与MRD阴性对照组的20.3%无显著差异(HR=1.272,p=.549)。
  • 预防性TKI组与对照组4年非复发死亡率分别为10.5%和9.7%(HR=1.094,p=.928),无显著差异。
  • 预防性TKI组与对照组4年总生存率分别为71.8%和84.1%(HR=1.746,p=.196),无显著差异。

核心结论

  • 作者认为,移植前MRD阳性的Ph+ ALL患者移植后预防性使用TKI可获得与移植前MRD阴性且移植后未用TKI者相当的结局。

研究设计与样本

  • 前瞻性多中心队列研究,共纳入110例接受异基因造血干细胞移植的Ph+ ALL患者。
  • 按移植前MRD状态分组:MRD阳性者38例进入预防性TKI组,MRD阴性者72例进入对照组。
  • 主要终点为累积复发率。

主要发现

  • 预防性TKI组与对照组4年累积复发率分别为25.3%(95%CI:12.1%-41.0%)和20.3%(95%CI:11.6%-30.7%),HR=1.272(95%CI:0.551-2.940),p=.549。
  • 预防性TKI组与对照组4年非复发死亡率分别为10.5%(95%CI:3.3%-22.7%)和9.7%(95%CI:4.2%-17.9%),HR=1.094(95%CI:0.320-3.738),p=.928。
  • 预防性TKI组与对照组4年总生存率分别为71.8%(95%CI:53.2%-84.1%)和84.1%(95%CI:72.9%-90.9%),HR=1.746(95%CI:0.741-4.112),p=.196。
  • 预防性TKI组与对照组4年白血病无病生存率分别为64.1%(95%CI:45.8%-77.7%)和70.0%(95%CI:57.6%-79.4%),HR=1.212(95%CI:0.607-2.421),p=.585。

临床怎么用

  • 作者认为,对移植前MRD阳性的Ph+ ALL患者,移植后预防性使用TKI可考虑用于获得与移植前MRD阴性者相当的结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Relapse is the major cause of treatment failure in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). This study aimed to evaluate the effect of a prophylactic tyrosine kinase inhibitor (TKI) strategy on relapse in this population. Patients were assigned to prophylactic or control groups based on measurable residual disease (MRD) pre-transplantation. The primary endpoint was the cumulative incidence of relapse. A total of 110 patients with Ph+ ALL undergoing allo-HSCT were enrolled in this prospective study. Thirty-eight patients with positive MRD pre-transplantation were included in the prophylactic group, and 72 with negative MRD pre-transplantation were included in the control group. The 4-year cumulative incidence of relapse was 25.3% (95% CI: 12.1%-41.0%) and 20.3% (11.6%-30.7%; HR = 1.272, 95% CI: 0.551-2.940, p = .549), and non-relapse mortality was 10.5% (3.3%-22.7%) and 9.7% (4.2%-17.9%; HR = 1.094, 95% CI: 0.320-3.738, p = .928) in the prophylactic and control groups. The 4-year overall survival was 71.8% (53.2%-84.1%) and 84.1% (72.9%-90.9%; HR = 1.746, 95% CI: 0.741-4.112, p = .196), and leukemia-free survival was 64.1% (45.8%-77.7%) and 70.0% (57.6%-79.4%; HR = 1.212, 95% CI: 0.607-2.421, p = .585) in the prophylactic and control groups. Our results suggest that prophylactic TKI post-HSCT in patients with positive MRD pre-transplantation can produce outcomes comparable to negative MRD pre-transplantation without TKI post-HSCT.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Liu H, Xu H, Chi P, et al. A prophylactic tyrosine kinase inhibitor strategy based on measurable residual disease pre-transplantation for Ph+ acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: A prospective multicenter cohort study. Am J Hematol. 2024. PMID: 39548804. doi:10.1002/ajh.27516

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。